drugset / Trial / NCT05388305
Universal CAR-γδT Cell Injection in the AML Patients
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the safety of general-purpose CAR-γδT cells in patients with refractory post-transplant relapsed AML.
Timeline
- Start
- 2022-04-20
- Primary completion
- 2023-04-30
- Completion
- 2023-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-γδT cells | Cell therapy | — | — |